Name of the Condition
- Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites (ICD-10 Code: C84.69)
Summary
Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites (ALCL, ALK-positive) is a rare subtype of non-Hodgkin lymphoma that primarily affects T-lymphocytes. It is characterized by the presence of the anaplastic lymphoma kinase (ALK) protein, resulting from a specific genetic rearrangement. This condition typically presents as a rapidly growing tumor involving sites outside the lymph nodes, such as the gastrointestinal tract, lung, bone, or other solid organs. ALCL, ALK-positive is more common in children and young adults and is generally considered aggressive but responsive to targeted therapies.
Causes
The exact cause of ALK-positive ALCL is not fully understood. The disease is driven by a genetic translocation involving the ALK gene, most commonly the t(2;5)(p23;q35) translocation, which results in overexpression of the ALK protein. This abnormal protein promotes uncontrolled cell growth and survival. While the translocation is a key driver, other genetic mutations may contribute to disease development, though specific environmental triggers remain unclear.
Risk Factors
- Age: More common in children and young adults, with a peak incidence in the second and third decades of life.
- Gender: Slightly higher prevalence in males.
- Genetic factors: Presence of the ALK translocation is a primary risk factor.
- Immunosuppression: Weakened immune systems may increase risk, though this is not a direct cause.
Symptoms
Symptoms depend on the site of involvement but may include localized swelling, pain, or mass in the affected organ; systemic symptoms such as fever, night sweats, or weight loss; and, if the disease is widespread, generalized fatigue or lymphadenopathy. Skin lesions or gastrointestinal symptoms (e.g., bleeding, obstruction) may occur if these sites are involved.
Diagnosis
Diagnosis involves a combination of clinical evaluation, imaging (e.g., CT, MRI, or PET scans) to identify tumor sites, and tissue biopsy. Histopathological analysis of biopsy samples confirms the presence of large, anaplastic cells, and immunohistochemistry or molecular testing detects the ALK protein or the associated genetic translocation. Staging studies assess the extent of disease.
Treatment Options
Treatment typically includes systemic therapy, such as chemotherapy (e.g., CHOP or more intensive regimens) and targeted therapy with ALK inhibitors (e.g., crizotinib) for ALK-positive cases. Radiation therapy may be used for localized disease. Stem cell transplantation is considered for relapsed or refractory cases. Treatment plans are tailored to the patient’s age, overall health, and disease extent.
Prognosis and Follow-Up
Prognosis varies based on disease stage, response to treatment, and patient factors. ALK-positive ALCL generally has a better prognosis than ALK-negative subtypes, with higher response rates to targeted therapy. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term survivors require ongoing surveillance for late effects of treatment.
Complications
Complications may include treatment-related toxicities (e.g., chemotherapy-induced organ damage, infection risk), disease progression or relapse, and rare instances of transformation to a more aggressive lymphoma. Organ-specific complications can arise if the disease involves critical structures (e.g., bowel obstruction, respiratory compromise).
Lifestyle & Prevention
No specific lifestyle measures prevent ALCL, as the disease is driven by genetic factors. Maintaining overall health, including a balanced diet, regular exercise, and avoiding known carcinogens (e.g., tobacco), supports general well-being. Patients in remission should follow their care team’s recommendations for activity and rest.
When to Seek Professional Help
Seek medical attention for persistent or worsening symptoms such as unexplained swelling, pain, fever, night sweats, or weight loss. Prompt evaluation is critical if symptoms suggest organ involvement (e.g., abdominal pain, difficulty breathing) or if treatment side effects (e.g., severe infection, bleeding) occur. Follow-up care is essential for monitoring disease status.
Tips for Medical Coders
Code C84.69 is specific to anaplastic large cell lymphoma, ALK-positive, involving extranodal and solid organ sites. Documentation should specify the ALK positivity and the non-lymph node site(s) affected (e.g., lung, bone, gastrointestinal tract) to support accurate coding. Ensure the diagnosis aligns with histopathological and molecular confirmation of ALK positivity, as this distinguishes it from ALK-negative or other lymphoma subtypes.